Mounjaro Injection

Mounjaro is a prescription medication developed by Eli Lilly and Company, designed to improve glycemic control in adults with type 2 diabetes. It is administered as a weekly subcutaneous injection and is available in various dosages, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL. The drug functions by activating both the GIP and GLP-1 receptors, enhancing insulin secretion, improving insulin sensitivity, and reducing food intake, thereby aiding in blood sugar regulation. Manufacturing of Mounjaro occurs in multiple countries to meet global demand. Eli Lilly and Company, headquartered in the United States, is the sole owner of the Mounjaro brand, with no known subsidiaries involved in its distribution or manufacturing.